For an individual who has been taking a standard three-drug antiretroviral regimen with suppressed viral loads and a history of documented M184V resistance mutation, which one of the following is true about a possible switch to bictegravir-tenofovir alafenamide-emtricitabine, based on clinical trial data?
a. This switch should not be offered because persistent low-level viremia is frequent after this specific switch
b. This switch is likely to maintain virologic suppression and could be offered
c. This switch is likely to maintain virologic suppression for about 4 to 6 weeks and then breakthrough viremia would be expected
d. Rates of virologic suppression are approximately 25% lower after this switch